Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection.
Study Type
OBSERVATIONAL
Enrollment
240
The ctDNA level will be measured using tumor-informed (Signatera platform) and tumor-naived (fragmentomes measurement) assay.
plasma protein level will be measured via Proximity Extension Assay and LC-MS based proteomic analysis
Zhongshan Hospital Fudan University
Shanghai, China
RECRUITINGCorrelation between ctDNA level and recurrence-free survival (RFS)
ctDNA measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Time frame: 1 years
Correlation between specific plasma protein expression level and recurrence-free survival (RFS)
plasma proteomic measurements will be made at baseline and 1 months, 3 months, 6 months, 12 months after surgery. RFS will be assessed by standard radiographic imaging.
Time frame: 1 years
Correlation between tumor mutation numbers and recurrence-free survival (RFS)
Patients with available tumor tissues were sequenced to identify their specific tumor variants.The correlation of mutation numbers and RFS will be analysis.
Time frame: 1 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.